M a t i T h e r a p e u t i c s I n c .
1
Designed and tested over 70 different iterations including “arrow” and “L”
shapes among others
Barrel L Design Arrowhead L Design
Straight L Design
Arrow Design
Retention rate of initial L-PPDS GLAU12 = 96% GLAU13 = 92%
High Retention rate continues on repeat insertion of L-PPDS 2nd cycle (8 weeks) = 97%
Solid drug-eluting core placed into our silicon punctal plug
Drug core wrapped in a non-permeable membrane and sealed with medical adhesive
Provides for one-directional drug release – directly into the tear film
X
X
X
Glaucoma Allergy Anti-Inflammatory Dry Eye
Prostglandins Mast Cell Stabilizers Steroids Soft Steroids
Beta-Blockers Antihistamines NSAIDs NSAIDs
Alpha Agonists OTC Demulcents
NCEs (ROK?) NCEs
Glaucoma Allergy Anti-Inflammatory Dry Eye
Prostglandins(Latanoprost, Brimatoprost, Travoprost)
Mast Cell Stabilizers Steroids Soft Steroids
Beta-Blockers Antihistamines NSAIDs(Nepafenac, Bromfenac)
NSAIDs
Alpha Agonists Olopatadine OTC Demulcents
NCEs (ROK?) NCEs
Mati now has 5 fully formulated ophthalmic agents including PGs, NSAIDs, and Mast Cell Stabilizers/Antihistamines.
-6.09
-5.35 -5.44-5.07
-5.56
-4.88-5.3
-5.06
-7
-6
-5
-4
-3
-2
-1
0
WK 1 WK 2 WK 3 WK 4 WK 6 WK 8 WK 10 WK 12
95% CI*Wk 4: (-6.11, -4.04), Wk 8: (-5.77, -3.99), Wk12:(-6.20, -3.93)
Ch
ang
e in
IOP
(mm
Hg
)
*95% CI excludes 0, indicating a p-value of <.05All IOP included, regardless of plug loss/removal
Adverse Event Percentage
Lacrimation (tearing) 13.1%
Eye Pruritis (itching) 10.7%
Conjunctival Hyperemia (redness) 7.6%
Punctate Keratitis (form of cornea inflammation) 6.7%
Eyelid Erythema (redness) 1.7%
Photophobia (light sensitivity) 0.5%
All Studies at 95µg Plug Concentration or Less, N=421
Serious AEs
Serious Adverse Event Occurrence
Skin Erosion 1 patient
Systemic 2 patients
0
2
4
6
8
10
12
14
0 5 10 15 20 25 30
Dru
g E
luti
on
Ra
te u
g/d
ay
Time (days)
L-PPDS
50% T-PPDS
30% T-PPDS
Beta-Blocker
Travoprost
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
0 5 10 15 20 25 30
Elu
tio
n r
ate
(m
icro
g/d
ay
)
Time (Days)
• Target elution : 3 μg/day for two weeks
Target μgFor desired efficacy
Initial burst is tunable to extend duration of action or power of
initial dose
IP portfolio consists of 62 issued patents and approximately 106 pending applications, comprising 15 patent families:
▪ Drug Core Design and Formulation▪ Lacrimal Implants▪ Manufacturing▪ Tools▪ Method of Use
Patent protection currently extends from approximately 2027-2034
Formulation Preclinical Phase I Phase II Phase III
Evolute® GlaucomaLatanoprost
Evolute® GlaucomaTravoprost
Evolute® Allergy(Olopatadine)
Evolute® Anti-Inflammatory(NSAID and/or steroid)
Multiple product opportunities for development from this platform• Allergy, Inflammation (NSAIDs & Steroids), Glaucoma (PGs, BetaBlockers, CAIs, Alpha 2s), Dry Eye
Wide Range of Compounds that can be Formulated Flexible Drug Delivery Profile Non-Invasive Approach Provides Relatively Steady Elution – Unlike Eye Drops Mati Plug is Comfortable and has Excellent Retention Preservative Free “Passive” System for Patients → Physician Controls Compliance
Reimbursement Paradigm Shift for General Ophthalmologists, Glaucoma Specialists, and Optometry
Strong IP Protection Reasonable COGS Projections